Digestive System Neoplasm

In a study of 468 colorectal adenocarcinoma 61 patients had micro-satellite instability (MSI) and there was a marginally statistically significantly better prognosis for BRAF WT (n=26) patients relati… (full text at CIViC)

PMID 27302369 · Schell et al., 2016 · Open in CIViC

5577 colon carcinoma tumors were evaluated for BRAF, KRAS, and mismatch repair status. From those successfully evaluated, 201 had microsatellite instability (MSI or MSI-H) and BRAF V600E, 72 had MSI a… (full text at CIViC)

PMID 28040692 · Taieb et al., 2017 · Open in CIViC

This clinical study was conducted with 30 patients with colorectal cancer harboring BRAF V600E (n = 29) or BRAF K601E (n=1) mutations, treated with a combination of cobimetinib and vemurafenib. Of the… (full text at CIViC)

PMID 36409971 · Klute et al., 2022 · Open in CIViC

In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to ma… (full text at CIViC)

PMID 31157963 · Golan et al., 2019 · Open in CIViC

In multicenter phase II study included individuals with a germline BRCA1/2 mutation and pancreatic cancer after gemcitabine treatment. Olaparib was administered at 400 mg twice per day. Tumor respons… (full text at CIViC)

PMID 25366685 · Kaufman et al., 2015 · Open in CIViC

Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=2… (full text at CIViC)

PMID 25072261 · Golan et al., 2014 · Open in CIViC

Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Five (21.7%) patients had a BRCA1 mutation. All but one had received prior gemcitabine, and 65% had … (full text at CIViC)

PMID 25366685 · Kaufman et al., 2015 · Open in CIViC

In the biliary tract carcinoma cohort of the phase II TAPUR trial (NCT02693535), patients with BRCA1/2 alterations treated with olaparib (18 evaluable) had 2 PR (BRCA1 loss n = 1, BRCA2 mutation n = 1… (full text at CIViC)

PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC

In this phase II study, 46 patients were enrolled (42 were evaluable; 27 gBRCA2, seven gBRCA1, six gPALB2, and two sBRCA2) and their chemotherapy was discontinued; patients then received rucaparib 600… (full text at CIViC)

PMID 33970687 · Reiss et al., 2021 · Open in CIViC

In pancreatic cell lines PL11 (FANCC-deficient) and CAPAN1 (BRCA2-mutated), sensitivity to DNA cross-linking agents was observed compared to FANCC/BRCA2 wildtype cell lines (Su86.86, CFPAC, AsPc1, and… (full text at CIViC)

PMID 16243825 · van der Heijden et al., 2005 · Open in CIViC

In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to ma… (full text at CIViC)

PMID 31157963 · Golan et al., 2019 · Open in CIViC

Patient with germline BRCA2 mutation underwent resection of pancreatic cancer. Around three years later, tumor recurrence was detected by MRI and PET-CT confirmed it. She was treated with gemcitabine … (full text at CIViC)

PMID 21508395 · Fogelman et al., 2011 · Open in CIViC

Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. In total of patients with BRCA1/2 mutation , all but … (full text at CIViC)

PMID 25366685 · Kaufman et al., 2015 · Open in CIViC

A patient with colorectal cancer harboring a CAD-ALK fusion gene was treated with the ALK inhibitor entrectinib, resulting in durable objective tumor response. A CT scan four weeks after treatment ini… (full text at CIViC)

PMID 26633560 · Amatu et al., 2015 · Open in CIViC

A patient with right-sided, MSI-High and CCDC6-RET positive metastatic colorectal cancer showed complete response to the selective RET inhibitor RXDX-105. The patient remained progression-free after 1… (full text at CIViC)

PMID 29538669 · Pietrantonio et al., 2018 · Open in CIViC

Cyclin D2 overexpression is associated with poor prognosis in gastric cancers.

PMID 10547574 · Takano et al., 1999 · Open in CIViC

Cyclin D2 overexpression is associated with the increased depth of cancer invasion in gastric cancers.

PMID 10547574 · Takano et al., 1999 · Open in CIViC

Cyclin D2 overexpression is associated with the presence pf lymph node metastasis in gastric cancers.

PMID 10547574 ·

CCND2 hypomethylation is seen to be more common in stage III and IV gastric tumors than stage I and II.

PMID 14612939 · Oshimo et al., 2003 · Open in CIViC

CCNE1 amplification has been found in 11–12% of gastric cancers and recent studies have shown that CCNE1 amplification is significantly associated with liver metastasis in a TP53-mutated gastric cance… (full text at CIViC)

PMID 31178228 · Kim et al., 2019 · Open in CIViC

Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma.

PMID 10224221 · Donnellan et al., 1999 · Open in CIViC

Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma.

PMID 10224221 · Donnellan et al., 1999 · Open in CIViC

465 gastric cancer samples and 15 corresponding liver metastases underwent IHC for PD1/PD-L1 protein expression. PD-L1 positivity in tumor cells was defined by at least 2% tumor cells with membranous … (full text at CIViC)

PMID 27009855 · Böger et al., 2016 · Open in CIViC

In a multivariate analysis from a clinical study including 123 resected primary gastric cancer, CD44s expression at invasive tumor front correlates with a decrease in survival (p< 0.0001). Moreover CD… (full text at CIViC)

PMID 27931044 · Kodama et al., 2017 · Open in CIViC

In a meta-analysis including nine trials with a total of 942 patients, high CD44v6 expression is significantly associated with a decrease in survival outcome (HR 2.13, 95% CI: 1.58 to 2.88).

PMID 25887688 · Fu et al., 2015 · Open in CIViC

In a meta-analysis including 4 studies with a total of 629 patients, CD44v6 expression is significantly correlated with a decrease in OS (HR 1.76, 95% IC: 1.30 to 2.39). One study that affects heterog… (full text at CIViC)

PMID 27977599 · Lu et al., 2016 · Open in CIViC

In a clinical study including 105 patients with resectable colorectal carcinomas, a Kaplan-Meier analysis showed a significant association between CD44v5 high expression and worse free time of disease… (full text at CIViC)

PMID 15300427 · Vizoso et al., 2004 · Open in CIViC

In a multivariate analysis from a clinical trial of 101 patients, CD44v6 expression combined with CD44s non-expression is significantly correlated with a reduced survival (p= 0.003).

PMID 24708709 · Li et al., 2014 · Open in CIViC

285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles. CDH1 mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognos… (full text at CIViC)

PMID 27313181 · Rokutan et al., 2016 · Open in CIViC

Cyclin-dependent kinase 9 (CDK9) was predominantly overexpressed in esophageal carcinoma tumor samples compared to normal esophageal cell lines. This high expression was also found in 90% of invasive … (full text at CIViC)

PMID 28404924 · Tong et al., 2017 · Open in CIViC

This preclinical study elucidated the potential varying efficaciousness of cyclin dependent Kinase inhibitor (CDK) dinaciclib. When forcing overexpression of differing CDKs (CDK1 and 9). Overall Hepat… (full text at CIViC)

PMID 31561409 · Shao et al., 2019 · Open in CIViC

112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1α and ALD… (full text at CIViC)

PMID 24708484 · Sim et al., 2014 · Open in CIViC

A phase II clinical study conducted with 12 patients with pancreatic cancer with CDKN2A loss or mutation treated with palbociclib. No clinical activity demonstrated in patients with CDKN2A mutated/del… (full text at CIViC)

PMID 35100714 · Al Baghdadi et al., 2019 · Open in CIViC

A phase II clinical study conducted in 10 patients with biliary cancer with CDKN2A loss or mutation, that were treated with palbociclib. No clinical activity demonstrated in patients with CDKN2A mutat… (full text at CIViC)

PMID 35100714 · Al Baghdadi et al., 2019 · Open in CIViC

In a phase 2 trial, patients with pancreatic cancer with CDKN2A loss or mutation were received palbociclib. Among 12 patients no overall response or stable disease at 16 weeks were observed.

Open in CIViC